Erythropoietin enhances immune responses in mice

European Journal of Immunology

Volumn 37, Issue 6, 2007, Pages 1584-1593

  Katz, Odelia ^a   Gil, Lidor ^a   Lifshitz, Lilach ^a   Prutchi Sagiv, Sara ^a   Gassmann, Max ^c   Mittelman, Moshe ^b   Neumann, Drorit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Erythropoietin; Immune response; Multiple myeloma

Indexed keywords

2,4 DINITROPHENOL; DINITROPHENYL ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; KEYHOLE LIMPET HEMOCYANIN; LIPOPOLYSACCHARIDE; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BONE MARROW DEPRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HEPATITIS B; HUMORAL IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; STRAIN DIFFERENCE; TRANSGENIC MOUSE; TUMOR IMMUNITY; VIRUS IMMUNITY; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD3; B-LYMPHOCYTES; CELL PROLIFERATION; ERYTHROPOIETIN; FEMALE; HEMOCYANIN; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN GAMMA-CHAINS; IMMUNOGLOBULIN KAPPA-CHAINS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE MYELOMA; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINATION;

EID: 34250675699     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200637025     Document Type: Article

References (65)

1. Cheer, S. M. and Wagstaff, A. J., Epoetin beta: a review of its clinical use in the treatment of anaemia in patients with cancer. Drugs 2004. 64: 323-346.
2. Gassmann, M., Heinicke, K., Soliz, J. and Ogunshola, O. O., Non-erythroid functions of erythropoietin. Adv. Exp. Med. Biol. 2003. 543: 323-330.
3. Buemi, M., Cavallaro, E., Floccari, F., Sturiale, A., Aloisi, C., Trimarchi, M., Corica, F. and Frisina, N., The pleiotropic effects of erythropoietin in the central nervous system. J. Neuropathol. Exp. Neurol. 2003. 62: 228-236.
4. Fraser, J. K., Tan, A. S., Lin, F. K. and Berridge, M. V., Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp. Hematol. 1989. 17: 10-16.
5. Sela, S., Shurtz-Swirski, R., Sharon, R., Manaster, J., Chezar, J., Shkolnik, G., Shapiro, G. et al., The polymorphonuclear leukocyte-a new target for erythropoietin. Nephron 2001. 88: 205-210.
6. Anagnostou, A., Liu, Z., Steiner, M., Chin, K., Lee, E. S., Kessimian, N. and Noguchi, C. T., Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 1994. 91: 3974-3978.
7. Jaquet, K., Krause, K., Tawakol-Khodai, M., Geidel, S. and Kuck, K. H., Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 2002. 64: 326-333.
8. Silverberg, D. S., Wexler, D., Blum, M., Tchebiner, J., Sheps, D., Keren, G., Schwartz, D. et al., The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clin. Nephrol. 2002. 58 Suppl 1: S37-45.
9. Fiordaliso, F., Chimenti, S., Staszewsky, L., Bai, A., Carlo, E., Cuccovillo, I., Doni, M. et al., A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 2005. 102: 2046-2051.
10. Genc, S., Koroglu, T. F. and Genc, K., Erythropoietin as a novel neuroprotectant. Restor. Neurol. Neurosci. 2004. 22: 105-119.
11. Grasso, G., Sfacteria, A., Cerami, A. and Brines, M., Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 2004. 10: 93-98.
12. Brines, M. and Cerami, A., Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 2005. 6: 484-494.
13. Jelkmann, W., Effects of erythropoietin on brain function. Curr. Pharm. Biotechnol. 2005. 6: 65-79.
14. Grimm, C., Wenzel, A., Groszer, M., Mayser, H., Seeliger, M., Samardzija, M., Bauer, C. et al., HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat. Med. 2002. 8: 718-724.
15. Kilic, E., Kilic, U., Soliz, J., Bassetti, C. L., Gassmann, M. and Hermann, D. M., Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB J. 2005. 19: 2026-2028.
16. Grimm, C., Hermann, D. M., Bogdanova, A., Hotop, S., Kilic, U., Wenzel, A., Kilic, E. and Gassmann, M., Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration. Semin. Cell. Dev. Biol. 2005. 16: 531-538.
17. Hasselblatt, M., Ehrenreich, H. and Siren, A. L., The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J. Neurosurg. Anesthesiol. 2006. 18: 132-138.
18. Prutchi-Sagiv, S., Neumann, D. and Mittelman, M., Erythropoietin as an immunotherapeutic agent: New uses for an old drug? Med. Hypoth. Res. 2005. 2: 587-596.
19. Sennesael, J. J., Van der Niepen, P. and Verbeelen, D. L., Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int. 1991. 40: 121-128.
20. Birmingham, D. J., Shen, X. P., Hartman, J. A., Dillon, J. J. and Hebert, L. A., Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. Kidney Int. 1996. 50: 543-549.
21. Hassan, K., Shternberg, L., Alhaj, M., Giron, R., Reshef, R., Barak, M. and Kristal, B., The effect of erythropoietin therapy and hemoglobin levels on the immune response to Engerix-B vaccination in chronic kidney disease. Ren. Fail. 2003. 25: 471-478.
22. Kimata, H., Yoshida, A., Ishioka, C. and Mikawa, H., Effect of recombinant human erythropoietin on human IgE production in vitro. Clin. Exp. Immunol. 1991. 83: 483-487.
23. Schaefer, R. M., Paczek, L., Berthold, G., Gilge, U. and Heidland, A., Improved immunoglobulin production in dialysis patients treated with recombinant erythropoietin. Int. J. Artif. Organs 1992. 15: 204-208.
24. Anandh, U., Thomas, P. P., Shastry, J. C. and Jacob, C. K., A randomised controlled trial of intradermal hepatitis B vaccination and augmentation of response with erythropoietin. J. Assoc. Physicians India 2000. 48: 1061-1063.
25. Peces, R., de la Torre, M., Alcazar, R. and Urra, J. M., Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am. J. Kidney Dis. 1997. 29: 239-245.
26. Mittelman, M., Zeidman, A., Kanter, P., Katz, O., Oster, H., Rund, D. and Neumann, D., Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies. Eur. J. Haematol. 2004. 72: 155-165.
27. Prutchi-Sagiv, S., Golishevsky, N., Oster, H. S., Katz, O., Cohen, A., Naparstek E., Neumann, D. and Mittelman, M., Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Br. J. Haematol. 2006. 135: 660-672.
28. Mittelman, M., Neumann, D., Peled, A., Kanter, P. and Haran-Ghera, N., Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc. Natl. Acad. Sci. USA 2001. 98: 5181-5186.
29. Katz, O., Barzilay, E., Skaat, A., Herman, A., Mittelman, M. and Neumann, D., Erythropoietin induced tumour mass reduction in murine lymphoproliferative models. Acta Haematol. 2005. 114: 177-179.
30. Croese, J. W., Vas Nunes, C. M., Radl, J., van den Enden-Vieveen, M. H., Brondijk, R. J. and Boersma, W. J., The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br. J. Cancer 1987. 56: 555-560.
31. Ruschitzka, F. T., Wenger, R. H., Stallmach, T., Quaschning, T., de Wit, C., Wagner, K., Labugger, R. et al., Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc. Natl. Acad. Sci. USA 2000. 97: 11609-11613.
32. Vanderkerken, K., De Raeve, H., Goes, E., Van Meirvenne, S., Radl, J., Van Riet, I., Thielemans, K. and Van Camp, B., Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br. J. Cancer 1997. 76: 451-460.
33. Radl, J., Croese, J. W., Zurcher, C., Van den Enden-Vieveen, M. H. and de Leeuw, A. M., Animal model of human disease. Multiple myeloma. Am. J. Pathol. 1988. 132: 593-597.
34. Bruderer, U. and Heusser, C., Regulation of immunoglobulin isotype expression in mice by antibodies in immune complexes. Immunol. Lett. 1988. 17: 235-240.
35. Tsai, S. L., Sheen, I. S., Chien, R. N., Chu, C. M., Huang, H. C., Chuang, Y. L., Lee, T. H. et al., Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J. Biomed. Sci. 2003. 10: 120-135.
36. Shurtz-Swirski, R., Kristal, B., Shkolnik, T., Weissman, I., Shapiro, G. and Shasha, S. M., Short-term effect of erythropoietin on T-cell mitogenic proliferation in chronic renal failure patients. Nephron 1996. 72: 27-29.
37. Debska-Slizien, A., Rutkowski, B., Manitius, J., Zdrojewski, Z., Szolkiewicz, M., Bullo, B., Lizakowski, S. et al., [Influence of erythropoietin on immunological system of patients with chronic renal failure]. Pol. Merkuriusz Lek. 2003. 15: 326-327; discussion 327-329.
38. Singh, A. B., Singh, M., Palekar, S., Levy, S., Nunn, C. and Mann, R. A., The effects of recombinant human erythropoietin on the cell mediated immune response of renal failure patients. J. Med. 1992. 23: 289-302.
39. Ueki, Y., Nagata, M., Miyake, S. and Taminaga, Y., Lymphocyte subsets in hemodialysis patients treated with recombinant human erythropoietin. J. Clin. Immunol. 1993. 13: 279-287.
40. Bryl, E., Mysliwska, J., Debska-Slizien, A., Rachon, D., Bullo, B., Lizakowski, S., Mysliwski, A. and Rutkowski, B., The influence of recombinant human erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cultures in hemodialysis patients. Artif. Organs 1998. 22: 177-181.
41. Bryl, E., Mysliwska, J., Debska-Slizien, A., Trzonkowski, P., Rachon, D., Bullo, B., Zdrojewski, Z. et al., Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients. Artif. Organs 1999. 23: 809-816.
42. Quadracci, L. J., Ringden, O. and Krzymanski, M., The effect of uremia and transplantation on lymphocyte subpopulations. Kidney Int. 1976. 10: 179-184.
43. Donati, D., Degiannis, D., Combates, N., Raskova, J. and Raska, K., Jr., Effects of hemodialysis on activation of lymphocytes: analysis by an in vitro dialysis model. J. Am. Soc. Nephrol. 1992. 2: 1490-1497.
44. Girndt, M., Kohler, H., Schiedhelm-Weick, E., Meyer zum Buschenfelde, K. H. and Fleischer, B., T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. Kidney Int. 1993. 44: 359-365.
45. Crosnier, J., Jungers, P., Courouce, A. M., Laplanche, A., Benhamou, E., Degos, F., Lacour, B. et al., Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II. Haemodialysis patients. Lancet 1981. 1: 797-800.
46. Siddiqui, J. Y., Fitz, A. E., Lawton, R. L. and Kirkendall, W. M., Causes of death in patients receiving long-term hemodialysis. JAMA 1970. 212: 1350-1354.
47. Descamps-Latscha, B., Jungers, P. and Witko-Sarsat, V., Immune system dysregulation in uremia: role of oxidative stress. Blood Purif. 2002. 20: 481-484.
48. Finkelman, F. D., Holmes, J., Katona, I. M., Urban, J. F., Jr,, Beckmann, M. P., Park, L. S., Schooley, K. A. et al., Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 1990. 8: 303-333.
49. Zheng, B., Woo, P. C., Ng, M., Tsoi, H., Wong, L. and Yuen, K., A crucial role of macrophages in the immune responses to oral DNA vaccination against hepatitis B virus in a murine model. Vaccine 2001. 20: 140-147.
50. Kimata, H., Yoshida, A., Ishioka, C., Masuda, S., Sasaki, R. and Mikawa, H., Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium. Clin. Exp. Immunol. 1991. 85: 151-156.
51. Kimata, H., Yoshida, A., Ishioka, C. and Mikawa, H., Erythropoietin enhances immunoglobulin production and proliferation by human plasma cells in a serum-free medium. Clin. Immunol. Immunopathol. 1991. 59: 495-501.
52. Heath, W. R. and Carbone, F. R., Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 2001. 19: 47-64.
53. Brower, V., Erythropoietin may impair, not improve, cancer survival. Nat. Med. 2003. 9: 1439.
54. Henke, M., Laszig, R., Rube, C., Schafer, U., Haase, K. D., Schilcher, B., Mose, S. et al., Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003. 362: 1255-1260.
55. Henke, M., Mattern, D., Pepe, M., Bezay, C., Weissenberger, C., Werner, M. and Pajonk, F., Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J. Clin. Oncol. 2006. 24: 4708-4713.
56. Leyland-Jones, B., Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003. 4: 459-460.
57. Dunlop, E. A., Perry, M. J., Boland, M. P., Maxwell, A. P. and Lappin, T. R., Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener. Dis. 2006. 3: 94-100.
58. Acs, G., Zhang, P. J., McGrath, C. M., Acs, P., McBroom, J., Mohyeldin, A., Liu, S. et al., Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am. J. Pathol. 2003. 162: 1789-1806.
59. Acs, G., Acs, P., Beckwith, S. M., Pitts, R. L., Clements, E., Wong, K. and Verma, A., Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001. 61: 3561-3565.
60. Croese, J. W., Vissinga, C. S., Boersma, W. J. and Radl, J., Immune regulation of mouse 5T2 multiple myeloma. I. Immune response to 5T2 MM idiotype. Neoplasma 1991. 38: 457-466.
61. Vanderkerken, K., De Greef, C., Asosingh, K., Arteta, B., De Veerman, M., Vande Broek, I., Van Riet, I. et al., Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/ KalwRij mouse. Br. J. Cancer 2000. 82: 953-959.
62. Vanderkerken, K., Van Camp, B., De Greef, C., Vande Broek, I., Asosingh, K. and Van Riet, I., Homing of the myeloma cell clone. Acta Oncol. 2000. 39: 771-776.
63. Chen, X., Li, M., Le, X., Ma, W. and Zhou, B., Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection. Vaccine 2004. 22: 439-446.
64. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D. and Mitchell, J. B., Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987. 47: 936-942.
65. Neumann, D., Wikstrom, L., Watowich, S. S. and Ladish, H. F., Intermediates in degradation of the erythropoietin receptor accumulate and are degraded in lysosomes. J. Biol. Chem 1993. 268: 13639-13649.